<DOC>
	<DOC>NCT00858754</DOC>
	<brief_summary>This purpose of this study is to evaluate the safety and effectiveness of a subcutaneous (injection beneath the skin) form of methylnaltrexone in subjects who have cancer-related pain and constipation from taking opioids. The length of participation will be up to 7 weeks.</brief_summary>
	<brief_title>Study Evaluating Safety &amp; Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics, Opioid</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Is a man or woman aged 18 years or older. Has a body weight &gt;= 38 kg. Has cancer (active or in remission), and has cancerrelated pain (ie, pain due to cancer or treatment of cancer). Has a life expectancy of &gt;= 6 months. Has a performance status of 0, 1, or 2 based on the Eastern Cooperative Oncology Group (ECOG) scale. Is taking opioids for cancerrelated pain, and not just asneeded doses. Has a diagnosis of OIC as determined by the investigator. Is willing to follow the protocol instructions on laxative use during the study. Has a history of chronic constipation before starting opioids. Has renal disease receiving dialysis. Has an ostomy for stools. Is a pregnant or breastfeeding woman.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>opioid induced constipation</keyword>
	<keyword>Cancer patients</keyword>
	<keyword>methylnaltrexone</keyword>
</DOC>